Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 07, 2020 16:05 ET | Source: Emergent BioSolutions

Emergent BioSolutions Announces Successful Completion of Offering of 3.875% Senior Unsecured Notes Due 2028

GAITHERSBURG, Md., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) (the “Company”) announced today that it has completed its previously announced offering of $450 million in...
August 04, 2020 18:31 ET | Source: Emergent BioSolutions

Emergent BioSolutions Announces Upsize and Pricing of $450 Million of 3.875% Senior Unsecured Notes Due 2028

GAITHERSBURG, Md., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) (the “Company”) announced today that it has priced its offering of $450 million aggregate principal amount...
June 03, 2019 06:30 ET | Source: Emergent BioSolutions

Emergent BioSolutions Awarded 10-Year HHS Contract Valued at Approximately $535 Million to Deliver Vaccinia Immune Globulin Intravenous (VIGIV) in Support of Smallpox Preparedness

GAITHERSBURG, Md., June 03, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract award by the Office of the Assistant Secretary for Preparedness and Response...
May 09, 2019 06:30 ET | Source: Emergent BioSolutions

Emergent BioSolutions to Hold Annual Meeting of Stockholders on Thursday, May 23, 2019 at 9:00 AM EDT; Webcast Will Be Available

GAITHERSBURG, Md., May 09, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) has announced that it will hold its Annual Meeting of Stockholders on Thursday, May 23, 2019 beginning at...
March 19, 2019 06:30 ET | Source: Emergent BioSolutions

Emergent BioSolutions Initiates Phase 3 Clinical Study to Evaluate AV7909 for Post-Exposure Prophylaxis of Anthrax

GAITHERSBURG, Md., March 19, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 3 trial to evaluate the lot consistency, immunogenicity, and...
February 28, 2019 16:45 ET | Source: Emergent BioSolutions

Emergent BioSolutions Awarded U.S. Department of State Contract to Supply Medical Countermeasures For Chemical Warfare Agents

GAITHERSBURG, Md., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has signed an indefinite-delivery, indefinite-quantity (IDIQ) contract with the...
February 21, 2019 16:05 ET | Source: Emergent BioSolutions

Emergent BioSolutions Reports Fourth Quarter and Full Year 2018 Financial Results

GAITHERSBURG, Md., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the quarter and year ended December 31, 2018. FINANCIAL HIGHLIGHTS (in...
February 12, 2019 06:30 ET | Source: Emergent BioSolutions

Emergent BioSolutions Announces Appointment of Seamus Mulligan to its Board of Directors

GAITHERSBURG, Md., Feb. 12, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the appointment of Seamus Mulligan to the company’s Board of Directors effective March 19,...
October 15, 2018 16:30 ET | Source: Emergent BioSolutions

Emergent BioSolutions Completes Acquisition of Adapt Pharma and Flagship Product Narcan® (Naloxone HCI) Nasal Spray

GAITHERSBURG, Md., Oct. 15, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has completed its acquisition of Adapt Pharma and its flagship product NARCAN®...
August 02, 2018 16:30 ET | Source: Emergent BioSolutions

Emergent BioSolutions Reports Financial Results for Second Quarter and Six Months of 2018

Q2 2018 total revenues of $220 million, net income of $50 millionReaffirms full year 2018 financial forecast and operational goals GAITHERSBURG, Md., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Emergent...